Early reduction of serum-free light chains associates with renal recovery in myeloma kidney

Journal of the American Society of Nephrology

Volumn 22, Issue 6, 2011, Pages 1129-1136

  Hutchison, Colin A ^a   Cockwell, Paul ^a   Stringer, Stephanie ^a   Bradwell, Arthur ^b,c   Cook, Mark ^a   Gertz, Morie A ^d   Dispenzieri, Angela ^d   Winters, Jeffrey L ^d   Kumar, Shaji ^d   Rajkumar, S Vincent ^d   Kyle, Robert A ^d   Leung, Nelson ^d  

^a UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST   (United Kingdom)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^c Binding Site Group Ltd   (United Kingdom)

^d MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; FREE LIGHT CHAIN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; PROTEIN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BIOPSY; CHRONIC KIDNEY DISEASE; CLINICAL ARTICLE; CREATININE BLOOD LEVEL; DIALYSIS; FEMALE; FREE LIGHT CHAIN BLOOD LEVEL; GLOMERULUS FILTRATION RATE; HEMATOLOGICAL PARAMETERS; HUMAN; KIDNEY DISEASE; KIDNEY FAILURE; KIDNEY FUNCTION; KIDNEY RECOVERY; LIGHT CHAIN; MALE; MULTICENTER STUDY; MYELOMA KIDNEY; PREDICTOR VARIABLE; PRIORITY JOURNAL; SURVIVAL;

EID: 79957706775     PISSN: 10466673     EISSN: 15333450     Source Type: Journal    
DOI: 10.1681/ASN.2010080857     Document Type: Article

References (32)

1. Bladé J, Fernández-Llama P, Bosch F, Montolíu J, Lens XM, Montoto S, Cases A, Darnell A, Rozman C, Montserrat E: Renal failure in multiple myeloma: Presenting features and predictors of outcome in 94 patients from a single institution. Arch Intern Med 158: 1889-1893, 1998
2. Chow CC, Mo KL, Chan CK, Lo HK, Wong KS, Chan JCW: Renal impairment in patients with multiple myeloma. Hong Kong Med J 9: 78-82, 2003 (Pubitemid 36406687)
3. Rayner HC, Haynes AP, Thompson JR, Russell N, Fletcher J: Perspectives in multiple myeloma: Survival, prognostic factors and disease complications in a single centre between 1975 and 1988. Q J Med 79: 517-525, 1991
4. Torra R, Blade J, Cases A, López-Pedret J, Montserrat E, Rozman C, Revert L: Patients with multiple myeloma requiring long-term dialysis: Presenting features, response to therapy, and outcome in a series of 20 cases. Br J Haematol 91: 854-859, 1995
5. Knudsen LM, Hjorth M, Hippe E for the Nordic Myeloma Study Group: Renal failure in multiple myeloma: Reversibility and impact on the prognosis. Eur J Haematol 65: 175-181, 2000
6. Matsue K, Fujiwara H, Iwama K, Kimura S, Yamakura M, Takeuchi M: Reversal of dialysis-dependent renal failure in patients with advanced multiple myeloma: Single institutional experiences over 8 years. Ann Hematol 89: 291-297, 2009
7. Dimopoulos MA, Roussou M, Gavriatopoulou M, Zagouri F, Migkou M, Matsouka C, Barbarousi D, Christoulas D, Primenou E, Grapsa I, Terpos E, Kastritis E: Reversibility of renal impairment in patients with multiple myeloma treated with bortezomib-based regimens: Identification of predictive factors. Clin Lymphoma Myeloma 9: 302-306, 2009
8. Iványi B: Frequency of light chain deposition nephropathy relative to renal amyloidosis and Bence Jones cast nephropathy in a necropsy study of patients with myeloma. Arch Pathol Lab Med 114: 986-987, 1990
9. Herrera GA, Joseph L, Gu X, Hough A, Barlogie B: Renal pathologic spectrum in an autopsy series of patients with plasma cell dyscrasia. Arch Pathol Lab Med 128: 875-879, 2004 (Pubitemid 39014119)
10. Leung N, Gertz MA, Zeldenrust SR, Rajkumar SV, Dispenzieri A, Fervenza FC, Kumar S, Lacy MQ, Lust JA, Greipp PR, Witzig TE, Hayman SR, Russell SJ, Kyle RA, Winters JL: Improvement of cast nephropathy with plasma exchange depends on the diagnosis and on reduction of serum free light chains. Kidney Int 73: 1282-1288, 2008 (Pubitemid 351693147)
11. Hutchison CA, Bradwell AR, Cook M, Basnayake K, Basu S, Harding S, Hattersley J, Evans ND, Chappel MJ, Sampson P, Foggensteiner L, Adu D, Cockwell P: Treatment of acute renal failure secondary to multiple myeloma with chemotherapy and extended high cut-off hemodialysis. Clin J Am Soc Nephrol 4: 745-754, 2009
12. Haynes RJ, Read S, Collins GP, Darby SC, Winearls CG: Presentation and survival of patients with severe acute kidney injury and multiple myeloma: 20-year experience from a single centre. Nephrol Dial Transplant 25: 419-426, 2009
13. Hutchison CA, Harding S, Hewins P, Mead GP, Townsend J, Bradwell AR, Cockwell P: Quantitative assessment of serum and urinary polyclonal free light chains in patients with chronic kidney disease. Clin J Am Soc Nephrol 3: 1684-1690, 2008
14. Hutchison CA, Cockwell P, Reid S, Chandler K, Mead GP, Harrison J, Hattersley J, Evans ND, Chappell MJ, Cook M, Goehl H, Storr M, Bradwell AR: Efficient removal of immunoglobulin free light chains by hemodialysis for multiple myeloma: In vitro and in vivo studies. J Am Soc Nephrol 18: 886-895, 2007 (Pubitemid 46434505)
15. Ludwig H, Drach J, Graf H, Lang A, Meran JG: Reversal of acute renal failure by bortezomib-based chemotherapy in patients with multiple myeloma. Haematologica 92: 1411-1414, 2007 (Pubitemid 350144160)
16. Kastritis E, Anagnostopoulos A, Roussou M: Reversibility of renal failure in newly diagnosed multiple myeloma patients treated with high dose dexamethasone-containing regimens and the impact of novel agents. Haematologica 92: 546-549, 2007 (Pubitemid 350144300)
17. Chanan-Khan AA, Kaufman JL, Mehta J, Richardson PG, Miller KC, Lonial S, Munshi NC, Schlossman R, Tariman J, Singhal S: Activity and safety of bortezomib in multiple myeloma patients with advanced renal failure: A multicenter retrospective study. Blood 109: 2604-2606, 2007 (Pubitemid 46425908)
18. Hutchison CA, Harding S, Mead G, Goehl H, Storr M, Bradwell A, Cockwell P: Serum free-light chain removal by high cutoff hemodialysis: Optimizing removal and supportive care. Artif Organs 32: 910-917, 2008
19. Bradwell AR, Carr-Smith HD, Mead GP, Tang LX, Showell PJ, Drayson MT, Drew R: Highly sensitive automated immunoassay for immunoglobulin FLCs in serum and urine. Clin Chem 47: 673-680, 2001 (Pubitemid 32275810)
20. Hutchison CA, Plant T, Drayson M, Cockwell P, Kountouri M, Basnayake K, Harding S, Bradwell AR, Mead G: Serum free light chain measurement aids the diagnosis of myeloma in patients with severe renal failure. BMC Nephrol 9: 11, 2008
21. Katzmann JA, Kyle RA, Benson J, Larson DR, Snyder MR, Lust JA, Rajkumar SV, Dispenzieri A: Screening panels for detection of monoclonal gammopathies. Clin Chem 55: 1517-1522, 2009
22. Palladini G, Russo P, Bosoni T, Verga L, Sarais G, Lavatelli F, Nuvolone M, Obici L, Casarini S, Donadei S, Albertini R, Righetti G, Marini M, Graziani MS, Melzi D'Eril GV, Moratti R, Merlini G: Identification of amyloidogenic light chains requires the combination of serum-free light chain assay with immunofixation of serum and urine. Clin Chem 55: 499-504, 2009
23. Durie BG, Harousseau JL, Miguel JS, Bladé J, Barlogie B, Anderson K, Gertz M, Dimopoulos M, Westin J, Sonneveld P, Ludwig H, Gahrton G, Beksac M, Crowley J, Belch A, Boccadaro M, Cavo M, Turesson I, Joshua D, Vesole D, Kyle R, Alexanian R, Tricot G, Attal M, Merlini G, Powles R, Richardson P, Shimizu K, Tosi P, Morgan G, Rajkumar SV: International Myeloma Working Group: International uniform response criteria for multiple myeloma. Leukemia 20:1467-1473, 2006 (Pubitemid 44264086)
24. Dispenzieri A, Kyle R, Merlini G, Miguel JS, Ludwig H, Hajek R, Palumbo A, Jagannath S, Blade J, Lonial S, Dimopoulos M, Comenzo R, Einsele H, Barlogie B, Anderson K, Gertz M, Harousseau JL, Attal M, Tosi P, Sonneveld P, Boccadoro M, Morgan G, Richardson P, Sezer O, Mateos MV, Cavo M, Joshua D, Turesson I: International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders. Leukemia 23: 215-224, 2008
25. Shah JJ, Orlowski RZ: Proteasome inhibitors in the treatment of multiple myeloma. Leukemia 23: 1964-1979, 2009
26. Dimopoulos MA, Kastritis E, Rosinol L, Bladé J, Ludwig H: Pathogenesis and treatment of renal failure in multiple myeloma. Leukemia 22: 1485-1493, 2008
27. Ludwig H, Adam Z, Hajek R, Greil R, Tóthová E, Keil F, Autzinger EM, Thaler J, Gisslinger H, Lang A, Egyed M, Womastek I, Zojer N: Light chain-induced acute renal failure can be reversed by bortezomibdoxorubicin-dexamethasone in multiple myeloma: Results of a phase II study. J Clin Oncol 28: 4635-4641, 2010
28. Zucchelli P, Pasquali S, Cagnoli L, Ferrari G: Controlled plasma exchange trial in acute renal failure due to multiple myeloma. Kidney Int 33: 1175-1180, 1988
29. Johnson WJ, Kyle RA, Pineda AA, O'Brien PC, Holley KE: Treatment of renal failure associated with multiple myeloma. Plasmapheresis, hemodialysis, and chemotherapy. Arch Intern Med 150: 863-869, 1990 (Pubitemid 20122064)
30. Clark WF, Stewart AK, Rock GA, Sternbach M, Sutton DM, Barrett BJ, Heidenheim AP, Garg AX, Churchill DN, Canadian Apheresis Group: Plasma exchange when myeloma presents as acute renal failure: A randomised controlled trial. Ann Intern Med 143: 777-784, 2005
31. Hutchison CA, Cook M, Heyne N, Weisel K, Billingham L, Bradwell A, Cockwell P: European trial of free light chain removal by extended haemodialysis in cast nephropathy (EuLITE): A randomised control trial. Trials 9: 55-61, 2008
32. Fish R, Pinney J, Jain P, Addison C, Jones C, Jayawardene S, Booth J, Howie AJ, Ghonemy T, Rajabali S, Roberts D, White L, Khan S, Morgan M, Cockwell P, Hutchison CA: The incidence of majour hemorrhagic complications after renal biopsies in patients with monoclonal gammopathies. Clin J Am Soc Nephrol 5: 1977-1980, 2010